Treatment Patterns and Effectiveness of Tofacitinib in Patients Initiating Therapy for Rheumatoid Arthritis: Results from the CorEvitas Rheumatoid Arthritis Registry

D.A. Pappas, MD, MPH, Corrona Research Foundation, Albany, New York, USA.
J. O'Brien, ScD, CorEvitas, Waltham, Massachusetts, USA.
P.C. Moore, PhD, MS, CorEvitas, Waltham, Massachusetts, USA.
R. Dodge, MS, CorEvitas, Waltham, Massachusetts, USA.
R. Germino, PhD, Pfizer Inc, New York, New York, USA.
K.R. Masri, MD, RhMSUS, Pfizer Inc, Collegeville, Pennsylvania, USA.
C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
L.C. Cappelli, MD, MHS, Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

The registry is sponsored by CorEvitas, LLC, and the analyses based on secondary analysis of registry data were funded and sponsored by Pfizer.
DAP has acted as a consultant for AbbVie and Roche Hellas, has received speaker fees or honoraria from AbbVie, Novartis, Roche Hellas, and Sanofi, has acted as an advisor for Sanofi, is an employee, and stockholder of CorEvitas, LLC, and is a board member of the Corrona Research Foundation. JOB, PCM, and RD are employees of CorEvitas, LLC. RG and KRM are employees and stockholders of Pfizer Inc. COB has acted as a consultant for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer Inc, and Sanofi, and has received grant support from Bristol Myers Squibb. LCC has received research funding from Bristol Myers Squibb.

Address correspondence to Dr Karim Richard Masri, Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USA. Email: Karim.Masri@pfizer.com.

Article usage